Evidence map›Paper›PMID 24232739›Full record

ReviewMolecules (Basel, Switzerland)2013

Molecular MRI of atherosclerosis.

Alkystis Phinikaridou, Marcelo E Andia, Sara Lacerda, Silvia Lorrio, Marcus R Makowski, René M Botnar

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Alkystis PhinikaridouDivision of Imaging Sciences and Biomedical Engineering, King's College London, 4th Floor, Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK. rene.botnar@kcl.ac.uk.
Marcelo E Andia
Sara Lacerda
Silvia Lorrio
Marcus R Makowski
René M Botnar
King's College London · GBCharité - Universitätsmedizin Berlin · DEPontificia Universidad Católica de Chile · CLSt Thomas' Hospital · GBWellcome Trust · GB

Funding

British Heart Foundation PG/10/044/28343British Heart Foundation PG/10/44/28343British Heart Foundation RG/12/1/29262Wellcome TrustWellcome Trust WT 088641/Z/09/Z
6 · The paper itself

Abstract

Despite advances in prevention, risk assessment and treatment, coronary artery disease (CAD) remains the leading cause of morbidity and mortality in Western countries. The lion's share is due to acute coronary syndromes (ACS), which are predominantly triggered by plaque rupture or erosion and subsequent coronary thrombosis. As the majority of vulnerable plaques does not cause a significant stenosis, due to expansive remodeling, and are rather defined by their composition and biological activity, detection of vulnerable plaques with x-ray angiography has shown little success. Non-invasive vulnerable plaque detection by identifying biological features that have been associated with plaque progression, destabilization and rupture may therefore be more appropriate and may allow earlier detection, more aggressive treatment and monitoring of treatment response. MR molecular imaging with target specific molecular probes has shown great promise for the noninvasive in vivo visualization of biological processes at the molecular and cellular level in animals and humans. Compared to other imaging modalities; MRI can provide excellent spatial resolution; high soft tissue contrast and has the ability to simultaneously image anatomy; function as well as biological tissue composition and activity.

Indexed as

AnimalsAtherosclerosisContrast MediaCoronary Artery DiseaseHumansMagnetic Resonance ImagingContrast Media

Identifiers

PMID24232739
PMCPMC6270261
OpenAlexW1995691000

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.